62 new cure signals as trials climb to 21,500
LISTEN
Direct audio file (MP3)ClinicalTrials.gov’s census shows 21,500 active gene, cell, mRNA, and SI trials worldwide, and today’s wire adds 62 new signals alongside 16 new cure developments. On the research side, multiple Nature Medicine reports converge on cancer detection and treatment—pairing blood-based RNA biomarker work in ovarian cancer with phase 3 survival improvements for the KRAS G12C inhibitor divarasib. On the systems side, a “Nvidia scandal” signal indicates chip compute policy is becoming a sharper political battlefield, underscoring that the capital/AI phase transition will be shaped as much by governance as by breakthroughs. The practical takeaway: keep your attention on what gets validated quickly in humans—biomarkers with cohort replication and phase 3 outcomes—because those are the most legible paths from signal to cure. The window is still open.
Nvidia is adjusting its lobbying posture as chip curbs face a harder political battlefield.
If compute policy tightens or shifts abruptly, it can redistribute the advantage in AI-enabled drug discovery, affecting how fast humanity converts signals into cures.
Prioritize near-term translational outputs—validated blood-based RNA biomarkers and phase 3 survival/progression endpoints—because these are the highest-time-pressure indicators in the current pipeline.